Abstract
The incidence of intrahepatic cholangiocarcinoma (ICC) has been increasing in recent
years and now represents the second most common primary hepatic cancer in the United
States. The prognosis is dismal without surgical resection. In patients ineligible
to receive curative treatments, locoregional therapies represent a diverse array of
techniques that can stabilize or reverse tumor progression to improve overall survival
and reduce tumor-related symptoms. Transarterial chemoembolization (TACE) and transarterial
radioembolization (TARE) have been demonstrated to be efficacious methods for this
patient population. Deciding between these two options is challenging. This article
reviews the differences in patient selection, preprocedural evaluation, financial
considerations and availability, quality of life, and rates of complications and overall
survival.
Keywords
intrahepatic cholangiocarcinoma - locoregional therapy - transarterial chemoembolization
- transarterial radioembolization - interventional radiology
